ArticleDermatology and therapy2026
Expert Consensus on the Role of Dermocosmetics in Acne Management in the United Arab Emirates.
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAcne is a chronic inflammatory skin disorder with multiple pathogenic pathways. The aim of this initiative was to develop United Arab Emirates (UAE)-specific consensus statements supporting the clinical integration of dermocosmetics into acne management.
methodsAn expert panel comprising 13 eminent dermatologists practicing in the UAE completed a pre-meeting survey on local acne management practices, followed by a meeting to appraise the proposed consensus statements. Consensus required a ≥ 70% level of agreement through anonymous online voting.
resultsAccording to the pre-meeting survey, most patients with acne were aged 13-35 years. Acne-induced hyperpigmentation and scarring were the most common complications. Despite their potential benefits, dermocosmetics were underutilized in routine clinical practice. Some dermocosmetics contain dermatologically active ingredients with clinical evidence supporting benefits in acne-prone skin, particularly for barrier support, tolerability, oil control, photoprotection, maintenance, and adherence. In total, the expert panel developed seven consensus statements that endorsed the value of dermocosmetics as: (1) initial therapy in mild acne, (2) adjuvant therapy to enhance tolerability and adherence in moderate-to-severe acne, and (3) maintenance therapy to sustain remission and prevent relapse. They highlighted its benefits in acne-induced hyperpigmentation, especially in darker phototypes and oilier skin phenotypes, which are common in the UAE. Additionally, the expert panel advocated for individualized treatment strategies according to the need, skin type, and acne severity of each patient.
conclusionTo our knowledge, this represents the first UAE-specific consensus guiding the integration and standardization of dermocosmetics into acne management. The statements are aligned to international standards and can be adapted to other regions sharing similar characteristics as UAE.
Indexed as
Identifiers
42663857What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.